Receptor Activator of Nuclear Factor-kappa B
This graph shows the total number of publications written about "Receptor Activator of Nuclear Factor-kappa B" by people in the URMC Research Network by year, and whether "Receptor Activator of Nuclear Factor-kappa B" was a major or minor topic of these publication.
Below are the most recent publications written about "Receptor Activator of Nuclear Factor-kappa B" by people in Profiles.
-
Menon P, Yin G, Smolock EM, Zuscik MJ, Yan C, Berk BC. GPCR kinase 2 interacting protein 1 (GIT1) regulates osteoclast function and bone mass. J Cell Physiol. 2010 Nov; 225(3):777-85.
-
Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010 Nov; 69(11):1907-12.
-
Anandarajah AP, Schwarz EM. Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies. Adv Exp Med Biol. 2009; 649:85-99.
-
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008 May 15; 473(2):139-46.
-
Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007 Sep; 5(3):98-104.
-
Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9 Suppl 1:S1.
-
Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007; 9 Suppl 1:S7.
-
Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, Zhang H, Gao AC. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res. 2006 Mar 1; 12(5):1420-30.
-
Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. J Cell Biochem. 2006 Feb 1; 97(2):226-32.
-
Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, Boyce BF, Xing L. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem. 2006 Feb 17; 281(7):4326-33.
